This study demonstrated that vitreous injection of miR-126 into rats negatively regulates VEGFA expression and inhibits retinal neovascularization formation, demonstrating promising therapeutic potential for miR-126 in the treatment of ROP. This evidence concerns the gene VEGFA and retinopathy of prematurity.